- Home
- NBY vs KLTOW Comparison
NBY vs KLTOW Comparison
Compare NBY & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBY | KLTOW |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | N/A |
| IPO Year | 2007 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NBY | KLTOW |
|---|---|---|
| Price | $3.59 | $0.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 544.0K | N/A |
| Earning Date | 11-07-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $10,302,000.00 | N/A |
| Revenue This Year | $23.91 | N/A |
| Revenue Next Year | $32.05 | N/A |
| P/E Ratio | $122.79 | ★ N/A |
| Revenue Growth | ★ 390.34 | N/A |
| 52 Week Low | $0.46 | N/A |
| 52 Week High | $4.44 | N/A |
Technical Indicators
Market Signals| Indicator | NBY | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 88.20 | 45.83 |
| Support Level | $2.66 | $0.13 |
| Resistance Level | $1.11 | $0.15 |
| Average True Range (ATR) | 0.39 | 0.01 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 96.24 | 34.12 |
Price Performance
Historical ComparisonAbout NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.